Twitter Facebook Linked In Zone In Google Plus 
August 2018 Research Update

Liquid Biopsy Reveals Promising Biomarkers for Rectal and Brain Cancer Patients

During the recent American Association for Cancer Research meeting (AACR 2018), two research groups presented poster data on the potential diagnostic use of liquid biopsy in rectal cancer (1) and brain cancer (2). One group of researchers used total RNA extracted from blood of rectal cancer patients to improve the accuracy of treatment outcomes, and a second group used cerebrospinal fluid (CSF) of brain cancer patients to identify biomarkers that would improve diagnosis and treatment potential.

The standard treatment for advanced rectal cancer starts with neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines. CRT can provide several patient benefits, including tumor mass reduction, blocking tumor invasion, increasing the tumor resection rate and anus retention rate, and reducing the local cancer recurrence rate. Interestingly, some patients obtain large reductions in tumor burden from CRT alone, with as many as 15-20% of patients even showing complete reduction. After a period of 4-5 weeks, chemo is followed by radical surgical resection of the tumor bearing tissue. This surgery can vary significantly depending on the exact location of the tumor relative to the anus, size, and invasiveness.

Typically, prior to surgery, the rectal cancer is re-staged in terms of its appearance or severity. Restaging aids in predicting the likelihood of recurrence of rectal cancer following surgical resection, and it uses a classifying system based on tumor regression grade (TRG)...

Read More
Come and See Us
Next Generation Dx Summit
August 20-24, 2018
Washington, DC
The CRISPR-Cas Revolution
August 22-25, 2018
Cold Spring Harbor, NY
XXII International Roundtable on Nucleosides Nucleotides and Nucleic Acids (IRT)
August 26-30, 2018
UCSD Campus San Diego, CA
Streptavidin Mag Beads
Need the highest biotin binding capacity available for critical experiments? Accelerate your isolation process and efficiency with NanoLink® and MagnaLink® magnetic beads.
Modified Nucleotides
Find what you need in our catalog of over 200 modified nucleotides or contact us for a custom nucleotide synthesis.
TriLink CRISPR Technology:
The Next Generation Toolkit for CRISPR Cas9 Gene Editing

TriLink offers the highest quality gene editing toolkit on the market. Trust the TriLink Cas9 mRNA and sgRNA combination to take your CRISPR experiments from research to the clinic.

Purchase custom single guide RNA at a special reduced flat rate, and receive complimentary CleanCap™ Cas9 mRNA.

$1399 for one custom sgRNA (1µmol starting synthesis scale) and receive 20µg CleanCap Cas9 mRNA with your order at no additional cost.*

$2499 for two custom sgRNA (1µmol starting synthesis scale) and receive 100µg CleanCap Cas9 mRNA with your order at no additional cost.*

*See website for full details


Ask An Expert

I've identified the target sequence for a CRISPR Cas9 gene editing experiment. What components do I need?

To attain unmatched consistency between your CRISPR experimental replicates use the TriLink CleanCap Cas9 mRNA and high quality sgRNA. sgRNA, also known as Single Guide RNA, is a chimeric RNA composed of crRNA and tracrRNA, connected by a short RNA linker. The purpose of sgRNAs is to bind to Cas9 and direct the complex...

Read More
Zone In With The Zon Blog Post

Clinical Efficacy Found: Two Oligonucleotide Drugs for Transthyretin (TTR)-Related Amyloidosis (ATTR)

As detailed elsewhere, ATTR represents a class of life-threatening and progressing diseases that is associated with the misfolding of TTR, a major blood protein that is a carrier of retinol (vitamin A) and thyroxine (thyroid hormone T4).TTR is primarily (>95%) produced in the liver as a...

View Blog Post


© 2018 TriLink BioTechnologies | All Rights Reserved